MP57-07 ELEVATED BLOOD EOSINOPHIL LEVEL PREDICTS BETTER RESPONSE AND LONGER SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED BY SORAFENIB

Hai-Liang Zhang,Hongkai Wang,Ding-Wei Ye

DOI: https://doi.org/10.1016/j.juro.2014.02.1782

2014-01-01

Abstract:You have accessJournal of UrologyKidney Cancer: Advanced1 Apr 2014MP57-07 ELEVATED BLOOD EOSINOPHIL LEVEL PREDICTS BETTER RESPONSE AND LONGER SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED BY SORAFENIB Hai-liang Zhang, Hongkai Wang, and Ding-wei Ye Hai-liang ZhangHai-liang Zhang More articles by this author , Hongkai WangHongkai Wang More articles by this author , and Ding-wei YeDing-wei Ye More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1782AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives Previous studies on the predictive or prognostic factors for metastatic renal cell carcinoma (mRCC) have not included blood eosinophil level. It was hypothesized that this biomarker could have predictive value for the patients treated by sorafenib. Methods Sorafenib was administered to 146 clear cell subtype mRCC patients according to an institutional treatment protocol from Jun 2006 to Dec 2011. Before treatment and every 2 weeks after first administration of sorafenib, routine blood test including eosinophil level was performed. Oncological evaluation was performed every 8 weeks. ANOVA test was used to compare the treatment response to the blood eosinophil level. Kaplan-Meier and Cox regression analyses on progression free survival were performed. Results Baseline eosinophil percentage ranged from 0.5% to 4.3%, and 48 (32.9%) patients had an elevated eosinophil level higher than 5.0% at one month after sorafenib treatment. The best responses for the 146 patients were 3 CR (2.1%), 36 PR (24.6%), 96 SD (65.8%), and 11 PD (7.5%), with a median progression free survival (PFS) of 12.3 months and an overall survival time (OS) of 31.6 months. The eosinophil levels at one month after first drug administration were correlated to the best responses observed in the later oncological evaluations. Patients with CR and PR presents higher blood eosinophil levels than those with SD and PD as their best response, p=0.024, Figure 1. Furthermore, patients with elevated eosinophil percentage higher than 5.0% survived much longer than those with eosinophil percentage lower than 5.0%, p<0.001, Figure 2. Multivariate Cox Regression Model analysis revealed that ECOG performance status, Fuhrman nuclear grade, and elevated eosinophil level were independent prognostic factors for overall survival. Conclusions Elevated blood eosinophil level may be a novel predictor for the response of second-line sorafenib treatment in clear cell mRCC, and also an independent prognostic factor for overall survival in these patients. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e643-e644 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Hai-liang Zhang More articles by this author Hongkai Wang More articles by this author Ding-wei Ye More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...